Comparative Analysis of Local Control Prediction Using Different Biophysical Models for Non-Small Cell Lung Cancer Patients Undergoing Stereotactic Body Radiotherapy

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2017 Jul 12

PMID 28695127

Authors

Bao-Tian Huang

Wu-Zhe Zhang

Li-Li Wu

Pei-Xian Lin

Jia-Yang Lu

Affiliations

Soon will be listed here.

Abstract

Purpose: The consistency for predicting local control (LC) data using biophysical models for stereotactic body radiotherapy (SBRT) treatment of lung cancer is unclear. This study aims to compare the results calculated from different models using the treatment planning data.

Materials And Methods: Treatment plans were designed for 17 patients diagnosed with primary non-small cell lung cancer (NSCLC) using 5 different fraction schemes. The Martel model, Ohri model, and the Tai model were used to predict the 2-year LC value. The Gucken model, Santiago model, and the Tai model were employed to estimate the 3-year LC data.

Results: We found that the employed models resulted in completely different LC prediction except for the Gucken and the Santiago models which exhibited quite similar 3-year LC data. The predicted 2-year and 3-year LC values in different models were not only associated with the dose normalization but also associated with the employed fraction schemes. The greatest difference predicted by different models was up to 15.0%.

Conclusions: Our results show that different biophysical models influence the LC prediction and the difference is not only correlated to the dose normalization but also correlated to the employed fraction schemes.

Citing Articles

External validation of radiobiological models for local control prediction in lung cancer patients treated with stereotactic body radiation therapy.

Huang B, Lin P, Wang Y, Luo L Front Oncol. 2025; 14:1431140.

PMID: 39902122 PMC: 11788688. DOI: 10.3389/fonc.2024.1431140.

References

Xia T, Li H, Sun Q, Wang Y, Fan N, Yu Y . Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006; 66(1):117-25. DOI: 10.1016/j.ijrobp.2006.04.013. View

Zhang B, Zhu F, Ma X, Tian Y, Cao D, Luo S . Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer: a systematic review and meta-analysis. Radiother Oncol. 2014; 112(2):250-5. DOI: 10.1016/j.radonc.2014.08.031. View

Bonfili P, Di Staso M, Gravina G, Franzese P, Buonopane S, Solda F . Hypofractionated radical radiotherapy in elderly patients with medically inoperable stage I-II non-small-cell lung cancer. Lung Cancer. 2009; 67(1):81-5. DOI: 10.1016/j.lungcan.2009.03.023. View

Kestin L, Grills I, Guckenberger M, Belderbos J, Hope A, Werner-Wasik M . Dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance. Radiother Oncol. 2014; 110(3):499-504. DOI: 10.1016/j.radonc.2014.02.002. View

Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J . Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010; 303(11):1070-6. PMC: 2907644. DOI: 10.1001/jama.2010.261. View

Ohri N, Werner-Wasik M, Grills I, Belderbos J, Hope A, Yan D . Modeling local control after hypofractionated stereotactic body radiation therapy for stage I non-small cell lung cancer: a report from the elekta collaborative lung research group. Int J Radiat Oncol Biol Phys. 2012; 84(3):e379-84. PMC: 3867931. DOI: 10.1016/j.ijrobp.2012.04.040. View

Zhang J, Yang F, Li B, Li H, Liu J, Huang W . Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis. Int J Radiat Oncol Biol Phys. 2011; 81(4):e305-16. DOI: 10.1016/j.ijrobp.2011.04.034. View

Solda F, Lodge M, Ashley S, Whitington A, Goldstraw P, Brada M . Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort. Radiother Oncol. 2013; 109(1):1-7. DOI: 10.1016/j.radonc.2013.09.006. View

Koshy M, Malik R, Weichselbaum R, Sher D . Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2015; 91(2):344-50. DOI: 10.1016/j.ijrobp.2014.10.002. View

10.

Hoffmann L, Jorgensen M, Muren L, Petersen J . Clinical validation of the Acuros XB photon dose calculation algorithm, a grid-based Boltzmann equation solver. Acta Oncol. 2011; 51(3):376-85. DOI: 10.3109/0284186X.2011.629209. View

11.

Dunlap N, Larner J, Read P, Kozower B, Lau C, Sheng K . Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT). J Thorac Cardiovasc Surg. 2010; 140(3):583-9. DOI: 10.1016/j.jtcvs.2010.01.046. View

12.

Tsuruta Y, Nakata M, Nakamura M, Matsuo Y, Higashimura K, Monzen H . Dosimetric comparison of Acuros XB, AAA, and XVMC in stereotactic body radiotherapy for lung cancer. Med Phys. 2014; 41(8):081715. DOI: 10.1118/1.4890592. View

13.

Chandra A, Guerrero T, Liu H, Tucker S, Liao Z, Wang X . Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol. 2005; 77(3):247-53. DOI: 10.1016/j.radonc.2005.10.017. View

14.

Shibamoto Y, Miyakawa A, Otsuka S, Iwata H . Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules?. J Radiat Res. 2016; 57 Suppl 1:i76-i82. PMC: 4990108. DOI: 10.1093/jrr/rrw015. View

15.

Martin A, Gaya A . Stereotactic body radiotherapy: a review. Clin Oncol (R Coll Radiol). 2010; 22(3):157-72. DOI: 10.1016/j.clon.2009.12.003. View

16.

Fenkell L, Kaminsky I, Breen S, Huang S, van Prooijen M, Ringash J . Dosimetric comparison of IMRT vs. 3D conformal radiotherapy in the treatment of cancer of the cervical esophagus. Radiother Oncol. 2008; 89(3):287-91. DOI: 10.1016/j.radonc.2008.08.008. View

17.

Mutter R, Liu F, Abreu A, Yorke E, Jackson A, Rosenzweig K . Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer. Int J Radiat Oncol Biol Phys. 2011; 82(5):1783-90. PMC: 3580772. DOI: 10.1016/j.ijrobp.2011.03.053. View

18.

Tai A, Liu F, Gore E, Li X . An analysis of tumor control probability of stereotactic body radiation therapy for lung cancer with a regrowth model. Phys Med Biol. 2016; 61(10):3903-13. DOI: 10.1088/0031-9155/61/10/3903. View

19.

Dunlap N, Cai J, Biedermann G, Yang W, Benedict S, Sheng K . Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2009; 76(3):796-801. DOI: 10.1016/j.ijrobp.2009.02.027. View

20.

Shibamoto Y, Hashizume C, Baba F, Ayakawa S, Miyakawa A, Murai T . Stereotactic body radiotherapy using a radiobiology-based regimen for stage I non-small-cell lung cancer: five-year mature results. J Thorac Oncol. 2015; 10(6):960-4. DOI: 10.1097/JTO.0000000000000525. View